Addressing business partners and associates to mark the second anniversary of DuBiotech's launch at a dinner reception yesterday, Dr. Alkhayat said the project has generated immense interest among top global names in pharma and biotechnology.
'Our community is growing by the day and we have already licensed several companies in different locations at the free zone. A total of 22 companies have been issued licenses so far, and 15 more are in the process of being licensed,' he said.
Recalling the vision of His Highness Sheikh Mohammed bin Rashid Al Maktoum, UAE Vice President and Prime Minister and Ruler of Dubai, for DuBiotech, Dr. Alkhayat said the Dubai Biotechnology initiative was created as an incubator for researchers and scientists and as a centre for production, creativity and development.
'Two years down the road, I am proud that we are moving ahead positively in line with the vision of His Highness,' Dr. Alkhayat added.
'It has been an exciting period of growth. We have just completed the comprehensive regulatory framework for the biotechnology and pharmaceutical industry in partnership with the Research Triangle Institute International (RTI). DuBiotech has developed comprehensive Codes of Practice (COPs) based on international best practices covering all activities related to clinical research and clinical trials, manufacturing and environment, health and safety.'
Dr. Alkhayat said the DuBiotech laboratory complex would be completed by the second quarter of 2008. The complex will allow companies to conduct laboratory activities without the need to build their own dedicated facilities.
The 22-storey twin tower headquarters of DuBiotech will be completed by the last quarter of 2008. It will house regional sales and marketing offices for companies specialising in life sciences, including multinationals and start-ups.
Pre-built units comprising core-and-shell facilities will be available by the second quarter of 2008. Land for long-term lease is available for major projects like manufacturing, research centres, labs, hospitals etc.
The Dubai Biotechnology and Research Park, member of TECOM Investments, is dedicated to creating an advanced technical and community infrastructure to accelerate the growth of life sciences industry in the region. DuBiotech will be the centre of excellence in biotechnology, bridging research, education and industry through national and international collaboration.
Over 70 per cent DuBiotech infrastructure completed ahead of schedule
Over 70 per cent of basic infrastructure at the Dubai Biotechnology and Research Park (DuBiotech) has been completed ahead of the scheduled date of June 2007, according to Dr Abdulqader Alkhayat, Executive Director, DuBiotech.
- United Arab Emirates: Tuesday, February 06 - 2007 at 12:20
- PRESS RELEASE
Notes and media contacts
For further information, please contact:Zeba Ahmad
Associate Account Manager
JIWIN PR
Tel: +971 4 3613333
Fax: + 971 4 3688001
Posted by Anne-Birte Stensgaard, Senior News EditorTuesday, February 06 - 2007 at 12:20 UAE local time (GMT+4)
Replication or redistribution in whole or in part is expressly prohibited without the prior written consent of AME Info FZ LLC / Emap Limited.
Index : Company News : Dubai Holding : DuBiotech
Browse related articles
Browse related articlesToday's most read articles:
Disclaimer:
Articles in this section are primarily provided directly by the companies appearing or PR agencies which are solely responsible for the content. The companies concerned may use the above content on their respective web sites provided they link back to http://www.ameinfo.com
Any opinions, advice, statements, offers or other information expressed in this section of the AME Info Web site are those of the authors and do not necessarily reflect the views of AME Info FZ LLC / Emap Limited. AME Info FZ LLC / Emap Limited is not responsible or liable for the content, accuracy or reliability of any material, advice, opinion or statement in this section of the AME Info Web site.
For details about submitting your stories, please read the guide - all content published is subject to our terms and conditions
Articles in this section are primarily provided directly by the companies appearing or PR agencies which are solely responsible for the content. The companies concerned may use the above content on their respective web sites provided they link back to http://www.ameinfo.com
Any opinions, advice, statements, offers or other information expressed in this section of the AME Info Web site are those of the authors and do not necessarily reflect the views of AME Info FZ LLC / Emap Limited. AME Info FZ LLC / Emap Limited is not responsible or liable for the content, accuracy or reliability of any material, advice, opinion or statement in this section of the AME Info Web site.
For details about submitting your stories, please read the guide - all content published is subject to our terms and conditions




Web Feeds